Novel intriguing strategies attenuating to sarcopenia

Journal of Aging Research

Volumn 2012, Issue , 2012, Pages

  Sakuma, Kunihiro ^a   Yamaguchi, Akihiko ^b  

^a TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; ANTIBODY; ANTIHYPERTENSIVE AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CORN OIL; CYCLOPHILIN D; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICOSAPENTAENOIC ACID; MYOSTATIN; NIFEDIPINE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PF 354; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; STAMULUMAB; UNCLASSIFIED DRUG; URSOLIC ACID;

AGING; ANTIINFLAMMATORY ACTIVITY; BECKER MUSCULAR DYSTROPHY; BETHLEM MYOPATHY; CACHEXIA; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; DRUG DISTRIBUTION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENDURANCE TRAINING; ENTERITIS; EPILEPSY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; HUMAN; HYPERTENSION; LIMB GIRDLE MUSCULAR DYSTROPHY; MITOCHONDRION; MUSCLE ATROPHY; MUSCULAR DYSTROPHY; MYOPATHY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84866035198     PISSN: 20902204     EISSN: 20902212     Source Type: Journal    
DOI: 10.1155/2012/251217     Document Type: Review

References (130)

1. Candow D. G., Chilibeck P. D., Differences in size, strength, and power of upper and lower body muscle groups in young and older men. Journals of Gerontology Series A: Biological Science Medical Science 2005 60 2 148 156 2-s2.0-17144362903 (Pubitemid 40524853)
2. Melton L. J. 3rd, Khosla S., Crowson C. S., O'Fallon W. M., Riggs B. L., Epidemiology of sarcopenia. Journal of the American Geriatrics Society 2000 48 6 625 630 2-s2.0-0034045298 (Pubitemid 30390451)
3. Baumgartner R. N., Waters D. L., Gallagher D., Morley J. E., Garry P. J., Predictors of skeletal muscle mass in elderly men and women. Mechanisms of Ageing and Development 1999 107 2 123 136 2-s2.0-0033104784 10.1016/S0047- 6374(98)00130-4 (Pubitemid 29138849)
4. Poehlnan E. T., Toth M. J., Fonong T., Exercise, substrate utilization and energy requirements in the elderly. International Journal of Obesity 1995 19 4 S93 S96
5. Griffiths R. D., Muscle mass, survival, and the elderly ICU patient. Nutrition 1996 12 6 456 458 2-s2.0-0030174928 10.1016/S0899-9007(96)00141-4 (Pubitemid 26295088)
6. Janssen I., Shepard D. S., Katzmarzyk P. T., Roubenoff R., The healthcare costs of sarcopenia in the United States. Journal of the American Geriatrics Society 2004 52 1 80 85 2-s2.0-0346499181 10.1111/j.1532-5415.2004.52014.x (Pubitemid 38090394)
7. Short K. R., Nair K. S., The effect of age on protein metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 2000 3 1 39 44 2-s2.0-0033929799 10.1097/00075197-200001000-00007 (Pubitemid 30469103)
8. Short K. R., Vittone J. L., Bigelow J. L., Proctor D. N., Nair K. S., Age and aerobic exercise training effects on whole body and muscle protein metabolism. American Journal of Physiology: Endocrinology and Metabolism 2004 286 1 E92 E101 2-s2.0-0347417903 (Pubitemid 38036614)
9. Lexell J., Human aging, muscle mass, and fiber type composition. Journals of Gerontology Series A: Biological Science and Medical Science 1995 50 11 16 2-s2.0-0028863055
10. Larsson L., Morphological and functional characteristics of the ageing skeletal muscle in man. A cross-sectional study. Acta Physiologica Scandinavica, Supplement 1978 457 1 36 2-s2.0-0018113372
11. Larsson L., Sjödin B., Karlsson J., Histochemical and biochemical changes in human skeletal muscle with age in sedentary males age 22-65 years. Acta Physiologica Scandinavica 1978 103 1 31 39 2-s2.0-0018151316 (Pubitemid 8349314)
12. Verdijk L. B., Koopman R., Schaart G., Meijer K., Savelberg H. H., van Loon L. J., Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. American Journal of Physiology: Endocrinology and Metabolism 2007 292 1 E151 E157 2-s2.0-33845999544 10.1152/ajpendo.00278.2006 (Pubitemid 46052937)
13. Verdijk L. B., Gleeson B. G., Jonkers R. A. M., Meijer K., Savelberg H. H. C. M., Dendale P., Van Loon L. J. C., Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men. Journals of Gerontology Series A: Biological Science and Medical Sciences 2009 64 3 332 339 2-s2.0-64849110613 10.1093/gerona/gln050
14. Brack A. S., Bildsoe H., Hughes S. M., Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. Journal of Cell Science 2005 118 20 4813 4821 2-s2.0-27844595300 10.1242/jcs.02602 (Pubitemid 41646389)
15. Collins C. A., Zammit P. S., Ruiz A. P., Morgan J. E., Partridge T. A., A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells 2007 25 4 885 894 2-s2.0-34147173390 10.1634/stemcells.2006-0372 (Pubitemid 46572585)
16. Day K., Shefer G., Shearer A., Yablonka-Reuveni Z., The depletion of skeletal muscle satellite cells with age is concomitant with reduced capacity of single progenitors to produce reserve progeny. Developmental Biology 2010 340 2 330 343 2-s2.0-77951204583 10.1016/j.ydbio.2010.01.006
17. Shefer G., van de Mark D. P., Richardson J. B., Yablonka-Reuveni Z., Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle. Developmental Biology 2006 294 1 50 66 2-s2.0-33646264523 10.1016/j.ydbio.2006.02.022
18. Conboy I. M., Conboy M. J., Smythe G. M., Rando T. A., Notch-mediated restoration of regenerative potential to aged muscle. Science 2003 302 5650 1575 1577 2-s2.0-0344827208 10.1126/science.1087573 (Pubitemid 37475703)
19. Roth S. M., Martel G. F., Ivey F. M., Lemmer J. T., Metter E. J., Hurley B. F., Rogers M. A., Skeletal muscle satellite cell populations in healthy young and older men and women. Anatomical Record 2000 260 4 351 358 2-s2.0-0034551759 10.1002/1097-0185(200012)260:4350::AID-AR30>3.0.CO;2-6
20. Wagers A. J., Conboy I. M., Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 2005 122 5 659 667 2-s2.0-24144489118 10.1016/j.cell.2005.08.021 (Pubitemid 41242632)
21. Lexell J., Ageing and human muscle: observations from Sweden. Canadian Journal of Applied Physiology 1993 18 1 2 18 2-s2.0-0027565841
22. Roubenoff R., Hughes V. A., Sarcopenia: current concepts. Journals of Gerontology Series A: Biologial Science and Medical Science 2000 55 12 M716 M724 2-s2.0-0034471472 (Pubitemid 32175754)
23. Sakuma K., Akiho M., Nakashima H., Akima H., Yasuhara M., Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles. Biochimica et Biophysica Acta Molecular Basis of Disease 2008 1782 7-8 453 461 2-s2.0-49649097995 10.1016/j.bbadis.2008.03.008
24. Sakuma K., Yamaguchi A., Molecular mechanisms in aging and current strategies to counteract sarcopenia. Current Aging Science 2010 3 2 90 101 2-s2.0-77953745513 10.2174/1874609811003020090
25. Sakuma K., Yamaguchi A., Sarcopenia: molecular mechanisms and current therapeutic strategy. Cell Aging 2011 Huntington, NY, USA Nova Science Publishers
26. Paddon-Jones D., Rasmussen B. B., Dietary protein recommendations and the prevention of sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care 2009 12 1 86 90 2-s2.0-58149133630 10.1097/MCO.0b013e32831cef8b
27. Bradley L., Yaworsky P. J., Walsh F. S., Myostatin as a therapeutic target for musculoskeletal disease. Cellular and Molecular Life Sciences 2008 65 14 2119 2124 2-s2.0-47749099634 10.1007/s00018-008-8077-3
28. Sakuma K., Yamaguchi A., Inhibitors of myostatin- and proteasome-dependent signaling for attenuating muscle wasting. Recent Patents on Regenerative Medicine 2011 1 3 284 298
29. Kunkel S. D., Suneja M., Ebert S. M., Bongers K. S., Fox D. K., Malmberg S. E., Alipour F., Shields R. K., Adams C. M., mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metabolism 2011 13 6 627 638 10.1016/j.cmet.2011.03.020
30. Smith G. I., Atherton P., Reeds D. N., Mohammed B. S., Rankin D., Rennie M. J., Mittendorfer B., Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. American Journal of Clinical Nutrition 2011 93 2 402 412 10.3945/ajcn.110.005611
31. McPherron A. C., Lawler A. M., Lee S. J., Regulation of skeletal muscle mass in mice by a new TGF- β superfamily member. Nature 1997 387 6628 83 90 2-s2.0-0031010050 (Pubitemid 27202654)
32. Lee S. J., Regulation of muscle mass by myostatin. Annual Review of Cell and Developmental Biology 2004 20 61 86 2-s2.0-8444243360 10.1146/annurev. cellbio.20.012103.135836 (Pubitemid 39488633)
33. Langley B., Thomas M., Bishop A., Sharma M., Gilmour S., Kambadur R., Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. Journal of Biological Chemistry 2002 277 51 49831 49840 2-s2.0-0037147210 10.1074/jbc.M204291200 (Pubitemid 36014431)
34. Thomas M., Langley B., Berry C., Sharma M., Kirk S., Bass J., Kambadur R., Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast differentiation. Journal of Biological Chemistry 2000 275 51 40235 40243 2-s2.0-0034704106 10.1074/jbc.M004356200 (Pubitemid 32064654)
35. Yang W., Zhang Y., Li Y., Wu Z., Zhu D., Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 β pathway and is antagonized by insulin-like growth factor 1. Journal of Biological Chemistry 2007 282 6 3799 3808 2-s2.0-33947538814 10.1074/jbc.M610185200 (Pubitemid 47084479)
36. McPherron A. C., Lee S. J., Double muscling in cattle due to mutations in the myostatin gene. Proceedings of the National Academy of Sciences of the United States of America 1997 94 23 12457 12461 2-s2.0-0030840359 10.1073/pnas.94.23.12457 (Pubitemid 27492550)
37. Schuelke M., Wagner K. R., Stolz L. E., Hübner C., Riebel T., Kömen W., Braun T., Tobin J. F., Lee S. J., Myostatin mutation associated with gross muscle hypertrophy in a child. New England Journal of Medicine 2004 350 26 2682 2688 2-s2.0-2942735123 10.1056/NEJMoa040933 (Pubitemid 38788003)
38. Allen D. L., Unterman T. G., Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. American Journal of Physiology: Cell Physiology 2007 292 1 C188 C199 2-s2.0-33846332013 10.1152/ajpcell.00542.2005 (Pubitemid 46115130)
39. Léger B., Derave W., de Bock K., Hespel P., Russell A. P., Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Research 2008 11 1 163 175 2-s2.0-39449100832 10.1089/rej.2007.0588 (Pubitemid 351271633)
40. Carlson M. E., Hsu M., Conboy I. M., Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008 454 7203 528 532 2-s2.0-47949097215 10.1038/nature07034
41. Haddad F., Adams G. R., Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. Journal of Applied Physiology 2006 100 4 1188 1203 2-s2.0-33646357762 10.1152/japplphysiol.01227.2005 (Pubitemid 43671476)
42. Bogdanovich S., Krag T. O., Barton E. R., Morris L. D., Whittemore L. A., Ahima R. S., Khurana T. S., Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002 420 6914 418 421 2-s2.0-0037191752 10.1038/nature01154 (Pubitemid 35415652)
43. Holzbaur E. L., Howland D. S., Weber N., Wallace K., She Y., Kwak S., Tchistiakova L. A., Murphy E., Hinson J., Karim R., Tan X. Y., Kelley P., McGill K. C., Williams G., Hobbs C., Doherty P., Zaleska M. M., Pangalos M. N., Walsh F. S., Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiology of Disease 2006 23 3 697 707 2-s2.0-33747223762 10.1016/j.nbd.2006.05.009
44. Wagner K. R., Fleckenstein J. L., Amato A. A., Barohn R. J., Bushby K., Escolar D. M., Flanigan K. M., Pestronk A., Tawil R., Wolfe G. I., Eagle M., Florence J. M., King W. M., Pandya S., Straub V., Juneau P., Meyers K., Csimma C., Araujo T., Allen R., Parsons S. A., Wozney J. M., LaVallie E. R., Mendell J. R., A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Annals of Neurology 2008 63 5 561 571 2-s2.0-44849140764 10.1002/ana.21338
45. Siriett V., Platt L., Salerno M. S., Ling N., Kambadur R., Sharma M., Prolonged absence of myostatin reduces sarcopenia. Journal of Cellular Physiology 2006 209 3 866 873 2-s2.0-33750527757 10.1002/jcp.20778 (Pubitemid 44665708)
46. LeBrasseur N. K., Schelhorn T. M., Bernardo B. L., Cosgrove P. G., Loria P. M., Brown T. A., Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. Journals of Gerontology Series A: Biological Science and Medical Sciences 2009 64 9 940 948 2-s2.0-68949108753 10.1093/gerona/glp068
47. Murphy K. T., Koopman R., Naim T., Léger B., Trieu J., Ibebunjo C., Lynch G. S., Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB Journal 2010 24 11 4433 4442 2-s2.0-78649853041 10.1096/fj.10-159608
48. Welle S., Burgess K., Mehta S., Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. American Journal of Physiology: Endocrinology and Metabolism 2009 296 3 E567 E572 2-s2.0-64749116516 10.1152/ajpendo.90862.2008
49. Amirouche A., Durieux A. C., Banzet S., Koulmann N., Bonnefoy R., Mouret C., Bigard X., Peinnequin A., Freyssenet D., Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 2009 150 1 286 294 2-s2.0-58149471229 10.1210/en.2008-0959
50. McFarlane C., Plummer E., Thomas M., Hennebry A., Ashby M., Ling N., Smith H., Sharma M., Kambadur R., Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF- κ B-independent, FoxO1-dependent mechanism. Journal of Cellular Physiology 2006 209 2 501 514 2-s2.0-33749254273 10.1002/jcp.20757 (Pubitemid 44484641)
51. Chelh I., Meunier B., Picard B., Reecy M. J., Chevalier C., Hocquette J. F., Cassar-Malek I., Molecular profiles of Quadriceps muscle in myostatin-null mice reveal PI3K and apoptotic pathways as myostatin targets. BMC Genomics 2009 10, article 196 13 2-s2.0-66049084853 10.1186/1471-2164-10-196
52. Frighetto R. T. S., Welendorf R. M., Nigro E. N., Frighetto N., Siani A. C., Isolation of ursolic acid from apple peels by high speed counter-current chromatography. Food Chemistry 2008 106 2 767 771 2-s2.0-34548317131 10.1016/j.foodchem.2007.06.003 (Pubitemid 47337150)
53. Liu J., Pharmacology of oleanolic acid and ursolic acid. Journal of Ethnopharmacology 1995 49 2 57 68 2-s2.0-0029567968 10.1016/0378-8741(95)01310-5 (Pubitemid 26010740)
54. Wang Z. H., Hsu C. C., Huang C. N., Yin M. C., Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice. European Journal of Pharmacology 2010 628 13 255 260 2-s2.0-73649098762 10.1016/j.ejphar.2009.11.019
55. Liu J., Oleanolic acid and ursolic acid: research perspectives. Journal of Ethnopharmacology 2005 100 1-2 92 94 2-s2.0-23044440041 10.1016/j.jep.2005. 05.024 (Pubitemid 41073528)
56. Zhang W., Hong D., Zhou Y., Zhang Y., Shen Q., Li J. Y., Hu L. H., Li J., Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochimica et Biophysica Acta 2006 1760 10 1505 1512 2-s2.0-33748882713 10.1016/j.bbagen.2006.05.009 (Pubitemid 44428024)
57. Kenner K. A., Anyanwu E., Olefsky J. M., Kusari J., Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. Journal of Biological Chemistry 1996 271 33 19810 19816 2-s2.0-0029810614 10.1074/jbc.271.33.19810 (Pubitemid 26281720)
58. Arterburn L. M., Hall E. B., Oken H., Distribution, interconversion, and dose response of n-3 fatty acids in humans. American Journal of Clinical Nutrition 2006 83 6 1467S 1476S 2-s2.0-33746809138 (Pubitemid 44713087)
59. Fearon K. C., von Meyenfeldt M. F., Moses A. G., Van Geenen R., Roy A., Gouma D. J., Giacosa A., Van Gossum A., Bauer J., Barber M. D., Aaronson N. K., Voss A. C., Tisdale M. J., Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003 52 10 1479 1486 2-s2.0-0141869044 10.1136/gut.52.10.1479 (Pubitemid 37176729)
60. Harper C. R., Jacobson T. A., Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. American Journal of Cardiology 2005 96 11 1521 1529 2-s2.0-28044446988 10.1016/j.amjcard.2005.07.071 (Pubitemid 41690172)
61. Bloomer R. J., Larson D. E., Fisher-Wellman K. H., Galpin A. J., Schilling B. K., Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids in Health and Disease 2009 8, article 36 2-s2.0-69549138355 10.1186/1476-511X-8-36
62. Babcock T. A., Helton W. S., Espat N. J., Eicosapentaenoic acid (EPA): an antiinflammatory ω -3 fat with potential clinical applications. Nutrition 2000 16 11-12 1116 1118 2-s2.0-0033665278 10.1016/S0899-9007(00)00392-0
63. Singer P., Shapiro H., Theilla M., Anbar R., Singer J., Cohen J., Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Medicine 2008 34 9 1580 1592 2-s2.0-49749141035 10.1007/s00134-008-1142-4
64. Babcock T. A., Helton W. S., Hong D., Espat N. J., Omega-3 fatty acid lipid emulsion reduces LPS-stimulated macrophage TNF- α production. Surgical Infections 2002 3 2 145 149 2-s2.0-0036342122
65. Magee P., Pearson S., Allen J., The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation. Lipids in Health and Disease 2008 7, article 24 2-s2.0-49249134734 10.1186/1476-511X-7-24
66. Machado R. V., Mauricio A. F., Taniguti A. P. T., Ferretti R., Neto H. S., Marques M. J., Eicosapentaenoic acid decreases TNF- α and protects dystrophic muscles of mdx mice from degeneration. Journal of Neuroimmunology 2011 232 1-2 145 150 10.1016/j.jneuroim.2010.10.032
67. Fabre J. E., Rivard A., Magner M., Silver M., Isner J. M., Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999 99 23 3043 3049 2-s2.0-0033564447 (Pubitemid 29270435)
68. de Cavanagh E. M., Piotrkowski B., Basso N., Stella I., Inserra F., Ferder L., Fraga C. G., Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. The FASEB Journal 2003 17 9 1096 1098 2-s2.0-0038718692
69. Maggio M., Ceda G. P., Lauretani F., Pahor M., Bandinelli S., Najjar S. S., Ling S. M., Basaria S., Ruggiero C., Valenti G., Ferrucci L., Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects. 65 years of age (the InCHIANTI study). American Journal of Cardiology 2006 97 10 1525 1529 2-s2.0-33646474121 10.1016/j.amjcard.2005.11.089
70. Onder G., Penninx B. W. J. H., Balkrishnan R., Fried L. P., Chaves P. H. M., Williamson J., Carter C., Di Bari M., Guralnik J. M., Pahor M., Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002 359 9310 926 930 2-s2.0-0037117109 10.1016/S0140-6736(02)08024-8 (Pubitemid 34246382)
71. Dossegger L., Aldor E., Baird M. G., Braun S., Cleland J. G. F., Donaldson R., Jansen L. J., Joy M. D., Marin-Neto J. A., Nogueira E., Stahnke P. L., Storm T., Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failurea multicentre, double-blind, placebo-controlled trial. European Heart Journal 1993 14 18 23 2-s2.0-0027234354 (Pubitemid 23235352)
72. Schellenbaum G. D., Smith N. L., Heckbert S. R., Lumley T., Rea T. D., Furberg C. D., Lyles M. F., Psaty B. M., Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. Journal of the American Geriatrics Society 2005 53 11 1996 2000 2-s2.0-29244445119 10.1111/j.1532-5415.2005.53568.x (Pubitemid 41826081)
73. Sumukadas D., Witham M. D., Struthers A. D., McMurdo M. E. T., Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Canadian Medical Association Journal 2007 177 8 867 874 10.1503/cmaj.061339 (Pubitemid 47612819)
74. Leonetti G., Mazzola C., Pasotti C., Angioni L., Vaccarella A., Capra A., Botta G., Zanchetti A., Treatment of hypertension in the elderlyeffects on blood pressure, heart rate, and physical fitness. American Journal of Medicine 1991 90 S12 S13 2-s2.0-0025854446
75. Bunout D., Barrera G., de la Maza P. M., Leiva L., Backhouse C., Hirsch S., Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial. Journal of the Renin-Angiotensin- Aldosterone System 2009 10 2 77 84 2-s2.0-67650486295 10.1177/1470320309105338
76. Cai D., Frantz J. D., Tawa N. E. Jr., Melendez P. A., Oh B. C., Lidov H. G. W., Hasselgren P. O., Frontera W. R., Lee J., Glass D. J., Shoelson S. E., IKK β /NF- κ B activation causes severe muscle wasting in mice. Cell 2004 119 2 285 298 2-s2.0-5444262078 10.1016/j.cell.2004.09.027 (Pubitemid 39360909)
77. Mitch W. E., Goldberg A. L., Mechanisms of disease: mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. New England Journal of Medicine 1996 335 25 1897 1905 2-s2.0-0030593939 10.1056/NEJM199612193352507 (Pubitemid 26419198)
78. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S. H., Goldberg A. L., Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004 117 3 399 412 2-s2.0-11144356337 10.1016/S0092-8674(04)00400- 3 (Pubitemid 38534545)
79. Stitt T. N., Drujan D., Clarke B. A., Panaro F., Timofeyva Y., Kline W. O., Gonzalez M., Yancopoulos G. D., Glass D. J., The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 2004 14 3 395 403 2-s2.0-2042425906 10.1016/S1097-2765(04)00211-4 (Pubitemid 38591410)
80. Bossola M., Pacelli F., Costelli P., Tortorelli A., Rosa F., Doglietto G. B., Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology 2008 9 4 261 268 2-s2.0-46749089596 10.1007/s10522-008-9135-9
81. Pattison J. S., Folk L. C., Madsen R. W., Childs T. E., Booth F. W., Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiological Genomics 2004 15 34 43 2-s2.0-0346041564 (Pubitemid 38089551)
82. Combaret L., Dardevet D., Béchet D., Taillandier D., Mosoni L., Attaix D., Skeletal muscle proteolysis in aging. Current Opinion in Clinical Nutrition and Metabolic Care 2009 12 1 37 41 2-s2.0-58149129428 10.1097/MCO.0b013e32831b9c31
83. DeRuisseau K. C., Kavazis A. N., Powers S. K., Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Experimental Gerontology 2005 40 6 526 531 2-s2.0-21244450623 10.1016/j.exger.2005.04.005 (Pubitemid 40884506)
84. Welle S., Brooks A. L., Delehanty J. M., Needler N., Thornton C. A., Gene expression profile of aging in human muscle. Physiological Genomics 2003 14 149 159 2-s2.0-0242333986 (Pubitemid 37345223)
85. Whitman S. A., Wacker M. J., Richmond S. R., Godard M. P., Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age. Pflügers Archiv European Journal of Physiology 2005 450 6 437 446 2-s2.0-25644432770 10.1007/s00424-005-1473-8 (Pubitemid 41380702)
86. Clavel S., Coldefy A. S., Kurkdjian E., Salles J., Margaritis I., Derijard B., Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mechanisms of Ageing and Development 2006 127 10 794 801 2-s2.0-33748526240 10.1016/j.mad.2006.07.005 (Pubitemid 44374662)
87. Edström E., Altun M., Hägglund M., Ulfhake B., Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle. Journals of Gerontology: Series A Biological Sciences and Medical Sciences 2006 61 7 663 674 2-s2.0-33746611524 (Pubitemid 44148351)
88. Attaix D., Mosoni L., Dardevet D., Combaret L., Mirand P. P., Grizard J., Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. International Journal of Biochemistry and Cell Biology 2005 37 10 1962 1973 2-s2.0-23944525331 10.1016/j.biocel.2005.04.009 (Pubitemid 41206814)
89. Husom A. D., Peters E. A., Kolling E. A., Fugere N. A., Thompson L. V., Ferrington D. A., Altered proteasome function and subunit composition in aged muscle. Archives of Biochemistry and Biophysics 2004 421 1 67 76 2-s2.0-0346848909 10.1016/j.abb.2003.10.010 (Pubitemid 37543497)
90. Lee D. H., Proteasome inhibitors: valuable new tools for cell biologists. Trends in Cell Biology 1998 8 10 397 403 2-s2.0-0032189348 10.1016/S0962- 8924(98)01346-4 (Pubitemid 28458705)
91. Adams J., Palombella V. J., Sausville E. A., Johnson J., Destree A., Lazarus D. D., Maas J., Pien C. S., Prakash S., Elliott P. J., Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 1999 59 11 2615 2622 2-s2.0-0033152760 (Pubitemid 29269108)
92. Orlowski R. Z., Proteasome inhibitors in cancer therapy. Methods in Molecular Biology 1997 100 197 203
93. Bonuccelli G., Sotgia F., Capozza E., Gazzerro E., Minetti C., Lisanti M. P., Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007 6 10 1242 1248 2-s2.0-34548266210 (Pubitemid 47327991)
94. Gazzerro E., Assereto S., Bonetto A., Sotgia F., Scarfi S., Pistorio A., Bonuccelli G., Cilli M., Bruno C., Zara F., Lisanti M. P., Minetti C., Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. American Journal of Pathology 2010 176 4 1863 1877 2-s2.0-77950583657 10.2353/ajpath.2010.090468
95. Beehler B. C., Sleph P. G., Benmassaoud L., Grover G. J., Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Experimental Biology and Medicine 2006 231 3 335 341 2-s2.0-33644687189 (Pubitemid 43334321)
96. Bernardi P., Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiological Reviews 1999 79 4 1127 1155 2-s2.0-0032827410 (Pubitemid 29473313)
97. Zamzami N., Kroemer G., The mitochondrion in apoptosis: how Pandora's box opens. Nature Reviews Molecular Cell Biology 2001 2 1 67 71 2-s2.0-0035229427 10.1038/35048073 (Pubitemid 33676964)
98. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., Tsujimoto Y., Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005 434 7033 652 658 2-s2.0-15844407874 10.1038/nature03317 (Pubitemid 40488558)
99. Schinzel A. C., Takeuchi O., Huang Z., Fisher J. K., Zhou Z., Rubens J., Hetz C., Danial N. N., Moskowitz M. A., Korsmeyer S. J., Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America 2005 102 34 12005 12010 2-s2.0-24744460273 10.1073/pnas.0505294102 (Pubitemid 41291119)
100. Millay D. P., Sargent M. A., Osinska H., Baines C. P., Barton E. R., Vuagniaux G., Sweeney H. L., Robbins J., Molkentin J. D., Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nature Medicine 2008 14 4 442 447 2-s2.0-41849118741 10.1038/nm1736 (Pubitemid 351499389)
101. Wissing E. R., Millay D. P., Vuagniaux G., Molkentin J. D., Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscular Disorders 2010 20 11 753 760 2-s2.0-77957752614 10.1016/j.nmd.2010.06.016
102. -myopathic mice. British Journal of Pharmacology 2009 157 6 1045 1052 2-s2.0-65549104874 10.1111/j.1476-5381.2009.00316.x
103. Angelini C., The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle and Nerve 2007 36 4 424 435 2-s2.0-34848840925 10.1002/mus.20812 (Pubitemid 47512066)
104. Balaban B., Matthews D. J., Clayton G. H., Carry T., Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy long-term effect. American Journal of Physical Medicine and Rehabilitation 2005 84 11 843 850 2-s2.0-27544464241 10.1097/01.phm.0000184156.98671.d0 (Pubitemid 41546724)
105. Morissette M. R., Cook S. A., Buranasombati C., Rosenberg M. A., Rosenzweig A., Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. American Journal of Physiology: Cell Physiology 2009 297 5 C1124 C1132 2-s2.0-70449627618 10.1152/ajpcell.00043.2009
106. Trendelenburg A. U., Meyer A., Rohner D., Boyle J., Hatakeyama S., Glass D. J., Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. American Journal of Physiology: Cell Physiology 2009 296 6 C1258 C1270 2-s2.0-66749188280 10.1152/ajpcell.00105.2009
107. Wellen K. E., Thompson C. B., Cellular metabolic stress: considering how cells respond to nutrient excess. Molecular Cell 2010 40 2 323 332 2-s2.0-78649391422 10.1016/j.molcel.2010.10.004
108. Holloszy J. O., Regulation by exercise of skeletal muscle. Journal of Physiology and Pharmacology 2008 59 7 5 18 2-s2.0-63649121321
109. Dirks A. J., Leeuwenburgh C., Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radical Biology and Medicine 2004 36 1 27 39 2-s2.0-0347318125 10.1016/j.freeradbiomed.2003.10.003 (Pubitemid 38068289)
110. López-Lluch G., Hunt N., Jones B., Zhu M., Jamieson H., Hilmer S., Cascajo M. V., Allard J., Ingram D. K., Navas P., De Cabo R., Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proceedings of the National Academy of Sciences of the United States of America 2006 103 6 1768 1773 2-s2.0-32444437067 10.1073/pnas.0510452103 (Pubitemid 43228768)
111. Payne A. M., Dodd S. L., Leeuwenburgh C., Life-long calorie restriction in Fischer 344 rats attenuates age-related loss in skeletal muscle-specific force and reduces extracellular space. Journal of Applied Physiology 2003 95 6 2554 2562 2-s2.0-0345708253 (Pubitemid 37445002)
112. Philips T., Leeuwenburgh C., Muscle fiber specific apoptosis and TNF- α signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB Journal 2005 19 6 668 670 2-s2.0-16344385647 10.1096/fj.04-2870fje (Pubitemid 40471280)
113. Taaffe D. R., Sarcopeniaexercise as a treatment strategy. Australian Family Physician 2006 35 3 130 134 2-s2.0-33646458120
114. Marzetti E., Lees H. A., Wohlgemuth S. E., Leeuwenburgh C., Sarcopenia of aging: underlying cellular mechanisms and protection by calorie restriction. BioFactors 2009 35 1 28 35 2-s2.0-65549136627 10.1002/biof.5
115. Sandri M., Lin J., Handschin C., Yang W., Arany Z. P., Lecker S. H., Goldberg A. L., Spiegelman B. M., PGC-1 α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proceedings of the National Academy of Sciences of the United States of America 2006 103 44 16260 16265 2-s2.0-33750825245 10.1073/pnas.0607795103 (Pubitemid 44715184)
116. Anderson R., Prolla T., PGC-1 α in aging and anti-aging interventions. Biochimica et Biophysica Acta 2009 1790 10 1059 1066 2-s2.0-69949102009 10.1016/j.bbagen.2009.04.005
117. Handschin C., Kobayashi Y. M., Chin S., Seale P., Campbell K. P., Spiegelman B. M., PGC-1 α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes and Development 2007 21 7 770 783 2-s2.0-34147109662 10.1101/gad.1525107 (Pubitemid 46572357)
118. Wenz T., Diaz F., Hernandez D., Activation of the PPAR/PGC-1 α pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy. Journal of Applied Physiology 2008 106 1712 1719
119. Goodpaster B. H., Carlson C. L., Visser M., Kelley D. E., Scherzinger A., Harris T. B., Stamm E., Newman A. B., Attenuation of skeletal muscle and strength in the elderly: the health ABC study. Journal of Applied Physiology 2001 90 6 2157 2165 2-s2.0-0034996580 (Pubitemid 32467407)
120. Song M.-Y., Ruts E., Kim J., Janumala I., Heymsfield S., Gallagher D., Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. American Journal of Clinical Nutrition 2004 79 5 874 880 2-s2.0-2442600121 (Pubitemid 41103890)
121. Zamboni M., Mazzali G., Fantin F., Rossi A., di Francesco V., Sarcopenic obesity: a new category of obesity in the elderly. Nutrition, Metabolism and Cardiovascular Diseases 2008 18 5 388 395 2-s2.0-44449140366 10.1016/j.numecd.2007.10.002
122. Morley J. E., Baumgartner R. N., Roubenoff R., Mayer J., Nair K. S., Sarcopenia. Journal of Laboratory and Clinical Medicine 2001 137 4 231 243 2-s2.0-0035073967 10.1067/mlc.2001.113504 (Pubitemid 32296061)
123. Roth R. J., Le A. M., Zhang L., Kahn M., Samuel V. T., Shulman G. I., Bennett A. M., MAPK phosphatase-1 facilitates the loss of oxidative myofibers
124. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. Journal of Clinical Investigation 2009 119 3 573 581 2-s2.0-67650815430 10.1172/JCI37048
125. Bonnard C., Durand A., Peyrol S., Chanseaume E., Chauvin M. A., Morio B., Vidal H., Rieusset J., Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. Journal of Clinical Investigation 2008 118 2 789 800 2-s2.0-38849199866 10.1172/JCI32601 (Pubitemid 351206566)
126. Arany Z., Foo S. Y., Ma Y., Ruas J. L., Bommi-Reddy A., Girnun G., Cooper M., Laznik D., Chinsomboon J., Rangwala S. M., Baek K. H., Rosenzweig A., Spiegelman B. M., HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 α Nature 2008 451 7181 1008 1012 2-s2.0-39749140405 10.1038/nature06613 (Pubitemid 351301733)
127. Handschin C., Chin S., Li P., Liu F., Maratos-Flier E., LeBrasseur N. K., Yan Z., Spiegelman B. M., Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1 α muscle-specific knock-out animals. Journal of Biological Chemistry 2007 282 41 30014 30021 2-s2.0-35648937073 10.1074/jbc.M704817200 (Pubitemid 350035265)
128. Crunkhorn S., Dearie F., Mantzoros C., Gami H., Da Silva W. S., Espinoza D., Faucette R., Barry K., Bianco A. C., Patti M. E., Peroxisome proliferator activator receptor γ coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. Journal of Biological Chemistry 2007 282 21 15439 15450 2-s2.0-34447511610 10.1074/jbc.M611214200 (Pubitemid 47093279)
129. Wenz T., Rossi S. G., Rotundo R. L., Spiegelman B. M., Moraes C. T., Increased muscle PGC-1 α expression protects from sarcopenia and metabolic disease during aging. Proceedings of the National Academy of Sciences of the United States of America 2009 106 48 20405 20410 2-s2.0-73949099327 10.1073/pnas.0911570106
130. Arany Z., PGC-1 coactivators and skeletal muscle adaptations in health and disease. Current Opinion in Genetics and Development 2008 18 5 426 434 2-s2.0-56049107038 10.1016/j.gde.2008.07.018 (Pubitemid 50283238)